ArticleWorld journal of microbiology & biotechnology2025
Diospyros kaki L. (persimmon) as a potential antibiofilm agent against Acinetobacter pittii, Acinetobacter baumannii, and Pseudomonas aeruginosa isolated from diabetic foot patients.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The persimmon (Diospyros kaki L.) is used in folk medicine, pharmaceuticals and cosmetics. It has several reported benefits, including antibacterial and antibiofilm properties. This study focused on investigating potential active compounds of fresh persimmon extract against test bacteria (Acinetobacter pittii, Acinetobacter baumannii and Pseudomonas aeruginosa) isolated from diabetic foot (DF) patients regarding antibacterial and antibiofilm activities. Accordingly, antibacterial, antibiofilm and cellular proliferation abilities for PCS-201-102 human dermal fibroblast cell line of extracts were determined. The chemical compounds of extracts were determined by Q-TOF-MS Accurate-Mass. Eleven molecules according to the negative ESI mode and seven molecules according to the positive ESI mode were selected. The selected compounds were analyzed for binding affinities to biofilm associated OmpA protein (for A. baumannii and A. pittii) and the YfiBNR triple signal sequence (for P. aeruginosa), via in silico modelling. Then, these compounds with high binding energy were also tested in vitro for their antibacterial and antibiofilm properties. Although no significant antibacterial activity of extracts has been recorded, high results (80.80-68.61%) have been observed for antibiofilm activity. The extracts did not show toxicity. Aesculin and rutin demonstrated high binding energy to the relevant proteins. Aesculin inhibited biofilm formation by A. pittii (76.18%), A. baumannii (81.88%) and P. aeruginosa (75.25%), while rutin was also over 75% effective against A. baumannii (79.29%) and P. aeruginosa (75.64%). Considering the crucial role of biofilm structure in worsening the clinical course of DF, aesculin and rutin have the potential to be used as adjuvants in combination with other ingredients/antibiotics.
Indexed as
Identifiers
41442061What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.